NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator’s Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM)
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
For more information, please visit ClinicalTrials.gov
|Patient Population||Investigational Product(s)||Phase||Status|
|Malignant Pleural Mesothelioma||NGR-hTNF||III||Closed|